Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TVGN | PRESS-RELEASE | neutral | 5/10 | Tevogen Bio announced it is evaluating strategic acquisitions that could generate approximately $100 million in combined | May 28, 2026 |
| ALT | PRESS-RELEASE | bullish | 7/10 | Altimmune presented new 48-week data from the IMPACT Phase 2b trial of pemvidutide in MASH at the EASL Congress 2026. Th | May 28, 2026 |
| PMN | PRESS-RELEASE | neutral | 3/10 | ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated its timeline for the | May 28, 2026 |
| AKTX | PRESS-RELEASE | neutral | 4/10 | Akari Therapeutics announced CEO participation in a Virtual Investor interview discussing its first ASCO abstract accept | May 28, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for seve | May 28, 2026 |
| ENTX | PRESS-RELEASE | bullish | 6/10 | Entera Bio announced that multiple abstracts across its oral peptide pipeline were accepted for ENDO 2026, with new clin | May 28, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc announced that its majority-owned subsidiary NeuroThera received conditional TSX approval for the acquisition o | May 28, 2026 |
| PLYX | PRESS-RELEASE | mixed | 6/10 | Polaryx Therapeutics closed a $10M PIPE financing at ~$4.00/share, issuing 2.5M new shares. Proceeds will fund the Phase | May 28, 2026 |
| BMRA | PRESS-RELEASE | bullish | 6/10 | Biomerica entered a Master Services Agreement with a confidential life sciences company to develop proprietary IVD assay | May 28, 2026 |
| COGT | PRESS-RELEASE | bullish | 8/10 | Cogent Biosciences announced FDA acceptance of its NDA for bezuclastinib in combination with sunitinib for GIST, with Pr | May 28, 2026 |
| SLGL | PRESS-RELEASE | neutral | 5/10 | Revenue fell to $0.1M from $1.0M on a prior-year milestone payment. The company raised $33.1M in an oversubscribed offer | May 28, 2026 |
| ZBIO | PRESS-RELEASE | bullish | 7/10 | Zenas BioPharma submitted a Biologics License Application (BLA) to the FDA for obexelimab in IgG4-RD, based on positive | May 28, 2026 |
| MYGN | PRESS-RELEASE | neutral | 4/10 | Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection | May 27, 2026 |
| MNKD | PRESS-RELEASE | bullish | 7/10 | MannKind announced nine poster presentations at ADA 2026 covering Afrezza data in pediatric efficacy, treatment satisfac | May 27, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber filed a provisional patent for a Coaxial Dual-Propellant Grain Solid Rocket Motor (CDPG-SRM) that extends | May 27, 2026 |
| LNZA | PRESS-RELEASE | neutral | 1/10 | LanzaTech Inc. announced it will report its Q2 2026 results on August 14, 2026. | May 27, 2026 |
| ALT | PRESS-RELEASE | neutral | 2/10 | Altimmune announced management participation in upcoming investor conferences, a routine corporate event with no materia | May 27, 2026 |
| ERNA | PRESS-RELEASE | neutral | 4/10 | Ernexa Therapeutics provided a business update press release highlighting progress on its lead candidate ERNA-101, inclu | May 27, 2026 |
| NCEL | PRESS-RELEASE | neutral | 5/10 | NewcelX announced submission of a Pre-IND briefing package to the FDA for NCEL-101 (stem-cell-derived islet therapy) com | May 27, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of Novembe | May 27, 2026 |
| MDWD | PRESS-RELEASE | bearish | 5/10 | MediWound reported Q1 2026 revenue of $1.5M, down 62% YoY from $4.0M, and a net loss of $0.23 per share, wider than the | May 27, 2026 |
| APGE | PRESS-RELEASE | bullish | 7/10 | Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion i | May 27, 2026 |
| APGE | PRESS-RELEASE | bullish | 8/10 | Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic de | May 27, 2026 |
| AGMB | PRESS-RELEASE | neutral | 2/10 | Agomab Therapeutics held its Annual General Meeting on May 26, 2026. The press release announces the meeting results but | May 27, 2026 |
| ALGS | PRESS-RELEASE | neutral | 4/10 | Aligos Therapeutics presented 10 posters at the EASL Congress 2026, including new Phase 1 long-term follow-up data for p | May 27, 2026 |
| NBTX | PRESS-RELEASE | neutral | 5/10 | Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raisi | May 26, 2026 |
| JBIO | PRESS-RELEASE | neutral | 3/10 | Jade Biosciences announced the first participant has been dosed in a Phase 1 clinical trial of JADE201, a half-life exte | May 26, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics reported Q1 2026 net loss of $78.9M vs $18.0M in Q1 2025, with R&D expenses surging to $70.9M from | May 26, 2026 |
| APGE | PRESS-RELEASE | neutral | 6/10 | Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 8/10 | Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25 per unit, raising ~ | May 26, 2026 |